Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Commentary|Podcasts|May 6, 2025
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
Advertisement
Host Craig Beavers spoke with Lavinia Salama, PharmD, clinical assistant professor at the University of Wyoming, about cardio-kidney-metabolic syndrome and how pharmacists can be at the forefront of serving patients. Salama also discusses her work in rural communities and why pharmacists are so crucial for those patients.
Show Notes:
- SELECT trial of semaglutide:
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
Advertisement
Related to this article
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
4
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
5